Perceptive Advisors LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Perceptive Advisors LLC

$4.77 Billion
Q1 2024

A detailed history of Perceptive Advisors LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 10,794,876 shares of CERE stock, worth $441 Million. This represents 9.58% of its overall portfolio holdings.

Number of Shares

10,794,876

Previous 10,965,193 1.55%

Holding current value

$441 Million

Previous $465 Million 1.86%

% of portfolio

9.58%

Previous 11.33%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $6.96 Million - $7.37 Million	-170,317 Reduced 1.55%	10,794,876 $456 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $17.8 Million - $37.2 Million	876,808 Added 8.69%	10,965,193 $465 Million
Q2 2023 Aug 24, 2023	BUY	$23.9 - $35.38 $4.07 Million - $6.03 Million	170,317 Added 1.72%	10,088,385 $321 Million
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $81.4 Million - $121 Million	3,406,341 Added 52.31%	9,918,068 $315 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $36.3 Million - $59 Million	1,425,000 Added 28.01%	6,511,727 $184 Million

Q3 2021 Dec 03, 2021	SELL	$21.26 - $38.85 $1.9 Million - $3.46 Million	-89,140 Reduced 1.72%	5,086,727 $150 Million
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $11.3 Million - $20.7 Million	532,772 Added 11.47%	5,175,867 $153 Million
Q1 2021 May 17, 2021	BUY	$12.37 - $17.74 $1.23 Million - $1.76 Million	99,033 Added 2.18%	4,643,095 $63.7 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $44.6 Million - $83 Million	4,544,062 New	4,544,062 $75.3 Million

Others Institutions Holding CERE

# of Institutions

227

Shares Held

150M

Call Options Held

939K

Put Options Held

961K

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Market Cap $6.37B
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.

Account

Perceptive Advisors LLC Cerevel Therapeutics Holdings, Inc. Transaction History